Finance

Lists
Why is KYTX down 7.94%?
Dive Deeper
KYTX:NASDAQ
Kyverna Therapeutics Inc
$5.22
-7.94%
(-0.45) 1D
Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
$5.70
High
$5.84
Low
$5.09
Mkt. cap
322.82M
Avg. vol.
956.90K
Volume
822.31K
52-wk high
$13.67
52-wk low
$5.09
EPS
-$2.94
Shares outstanding
61.84M
No. of employees
149
Open
$5.70
High
$5.84
Low
$5.09
Mkt. cap
322.82M
Avg. vol.
956.90K
Volume
822.31K
52-wk high
$13.67
52-wk low
$5.09
EPS
-$2.94
Shares outstanding
61.84M
No. of employees
149
News stories
From web sources and news partners
About Kyverna Therapeutics Inc
CEO-
Employees149
Founded2018
HeadquartersEmeryville, California, United States
SectorBiotechnology
Websitekyvernatx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current $5.22
$33.00 (+532.18%)
Average
$30.33 (+481.03%)
Lowest
$25.00 (+378.93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+378.9%
10/26/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$33.00
+532.2%
09/25/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/24/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$33.00
+532.2%
08/12/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/12/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$29.00
+455.6%
05/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$30.00
+474.7%
03/30/2026
Next call in 10 days
Thu, Nov 12, 4:00 PM
Fiscal period
Q3 2026
- / -$0.69
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
30.46M
-103.71M
30.07M
-
Cost of revenue
30.46M
-103.71M
30.07M
-
Research and development expenses
-
133.72M
-
24.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.27M
9.27M
11.29M
14.77M
Operating expense
8.27M
142.99M
11.29M
39.56M
Total operating expenses
38.73M
39.28M
41.37M
39.56M
Operating income
-38.73M
-39.28M
-41.37M
-39.56M
Other non operating income
-53.00K
17.00K
-21.00K
-18.00K
EBT including unusual items
-36.79M
-37.80M
-39.73M
-38.32M
EBT excluding unusual items
-36.79M
-37.80M
-39.73M
-38.32M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.79M
-37.80M
-39.73M
-38.32M
Net profit margin
-
-
-
-
Earnings per share
-0.85
-0.80
-0.66
-0.63
Interest and investment income
2.00M
1.90M
2.33M
1.93M
Interest expense
-7.00K
-444.00K
-667.00K
-674.00K
Net interest expenses
1.99M
1.46M
1.66M
1.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.84M
-38.91M
-41.02M
-39.12M
Gain or loss from assets sale
40.00K
20.00K
-
-47.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps